| Prev Close | 268.35 |
| Open | 265.51 |
| Day Low/High | 263.78 / 268.00 |
| 52 Wk Low/High | 176.36 / 292.75 |
| Volume | 441.55K |
Vertex Pharmaceuticals Incorporated (VRTX)
266.52
1.80
0.68
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 255.76B |
| Market Cap | 66.14B |
| P/E Ratio | 23.27 |
| Div & Yield | N.A. (N.A) |
Corbus Ready to Take Cystic Fibrosis Drug the Distance Says CEO
It’s been a hot M&A market for biotech companies developing treatments for rare diseases.
Can Biotechs' Relative Strength Be Trusted? 6 Stocks to Watch
Sector may not be as bulletproof as we thought.
Cramer: I Like Receptos and Radius, as Well as the Four Horsemen
Jim Cramer answers viewers' stock questions from the floor of the New York Stock Exchange.
Picasso Painting Sells for a Record $179 Million Dollars at Auction
A Picasso Painting Fetched $179 million dollars at an auction at Christie's Monday night, the most ever paid for a work of art at auction.
3 Fantastic Pharmaceutical Stocks: Abbvie, Vertex and Biogen
AbbVie is a cheap stock and worries about competition immediately hurting its rheumatoid arthritis drug Humira are overblown, said John Schroer, Portfolio Manager for the AllianzGI Health Sciences Fund.
Earnings and Marriage Season
Biotech companies are saying, "I do."
Deal or No Deal, Stick With Mylan
Teva bid highlights M&A action in health care sector.
Deal or No Deal, Stick With Mylan
Teva bid highlights M&A action in health care sector.
Mylan Deal the Rx for Drug Stocks
Even the second-tier biotechs are taking off.
The 7 Pillars of Healthcare Strength
Here are healthcare stocks of all shares and sizes with strong charts.
Look Past the Indecision
We got the rally we were looking for -- so now what?
A Solid Bounce and Close
Watch the momentum names, which were the biggest positive today.
What to Buy in the Selloff
Here are several themes that are still working -- and now you can get in at a bargain.
Oracle Snags Micros Systems, Vertex Soars & America Exports Oil
Oracle announced Monday the purchase of Micros Systems for $5.3B and plans to combine their industry specific applications with its own.
A Few Off-the-Table Trades
You can always buy these names back.
Biotechs Flash the Green Light
After a decline, the sector has built a base, and these names are breaking out.
Taking Vertex's Temperature
Spreads are wide right now, so a patient entry is required.
Stocks for the Noncommittal
You don't need much conviction to trade these two names.
Who's Getting Busy Living?
These types of companies are winners today.
